AR134366A1 - Anticuerpo antitranstiretina, composiciones que comprenden dicho anticuerpo y métodos para tratar o prevenir la amiloidosis mediada por transtiretina - Google Patents

Anticuerpo antitranstiretina, composiciones que comprenden dicho anticuerpo y métodos para tratar o prevenir la amiloidosis mediada por transtiretina

Info

Publication number
AR134366A1
AR134366A1 ARP240103147A ARP240103147A AR134366A1 AR 134366 A1 AR134366 A1 AR 134366A1 AR P240103147 A ARP240103147 A AR P240103147A AR P240103147 A ARP240103147 A AR P240103147A AR 134366 A1 AR134366 A1 AR 134366A1
Authority
AR
Argentina
Prior art keywords
methods
antibody
compositions
treating
preventing
Prior art date
Application number
ARP240103147A
Other languages
English (en)
Inventor
Aubin Michalon
Michael Salzmann
Rahul Godawat
Siguang Sui
Original Assignee
Neurimmune Ag
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurimmune Ag, Alexion Pharma Inc filed Critical Neurimmune Ag
Publication of AR134366A1 publication Critical patent/AR134366A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Anticuerpos antitranstiretina (TTR), polinucleótidos correspondientes y vectores de expresión, así como composiciones (por ejemplo, composiciones farmacéuticas) y artículos de elaboración relacionados que contienen el anticuerpo anti-TTR como un fármaco. También métodos para tratar o prevenir la amiloidosis mediada por transtiretina (ATTR) en un sujeto que lo necesite con el uso de las composiciones farmacéuticas. Además, métodos para validar, identificar y cribar un fármaco que disminuye los amiloides con el uso de formación de imágenes de células vivas de alta resolución, así como métodos para producir una composición farmacéutica de un fármaco que disminuye los amiloides y kits adecuados para su uso en dichos métodos.
ARP240103147A 2023-11-15 2024-11-15 Anticuerpo antitranstiretina, composiciones que comprenden dicho anticuerpo y métodos para tratar o prevenir la amiloidosis mediada por transtiretina AR134366A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2023081969 2023-11-15
EP2024064293 2024-05-23
EP2024077454 2024-09-30

Publications (1)

Publication Number Publication Date
AR134366A1 true AR134366A1 (es) 2026-01-07

Family

ID=93562471

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240103147A AR134366A1 (es) 2023-11-15 2024-11-15 Anticuerpo antitranstiretina, composiciones que comprenden dicho anticuerpo y métodos para tratar o prevenir la amiloidosis mediada por transtiretina

Country Status (3)

Country Link
AR (1) AR134366A1 (es)
TW (1) TW202528347A (es)
WO (1) WO2025104243A1 (es)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
BR9808584A (pt) 1997-03-14 2000-05-23 Idec Pharma Corp Processo para integrar genes em sìtios especìficos em células de mamìferos via recombinação homóloga e vetores para obter os mesmos
DE60126130T2 (de) 2000-11-17 2007-10-18 The University Of Rochester In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen
US7319139B2 (en) 2001-01-29 2008-01-15 Biogen Idec, Inc. TAG-72 specific CH2 domain deleted antibodies
US20030157641A1 (en) 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
EP2906599B1 (en) 2012-10-12 2019-07-17 Agency For Science, Technology And Research Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics
EA201500741A1 (ru) * 2013-01-10 2016-01-29 Генмаб Б.В. ВАРИАНТЫ Fc-ОБЛАСТИ IGG1 ЧЕЛОВЕКА И ИХ ПРИМЕНЕНИЕ
US9790269B2 (en) 2013-02-08 2017-10-17 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
HUE051837T2 (hu) 2013-12-20 2021-03-29 Neurimmune Holding Ag Transztiretin (TTR) amiloidózis ellenanyag-alapú terápiája és ennek humán eredetû ellenanyagai
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007923A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3717512A4 (en) * 2017-11-29 2021-08-25 Prothena Biosciences Limited LYOPHILIZED FORMULATION OF A MONOCLONAL ANTIBODY AGAINST TRANSTHYRETIN
EP3876713B1 (en) 2018-11-09 2024-10-02 Neurimmune AG Patient-derived amyloid xenograft rodent model
MX2021012867A (es) * 2019-04-24 2022-03-04 Regenxbio Inc Terapéutica de anticuerpos postraduccionalmente modificados completamente humanos.
MX2022014223A (es) 2020-05-12 2023-04-14 Neurimmune Ag Terapia de combinacion para amiloidosis de la ttr.
WO2023099788A1 (en) 2021-12-03 2023-06-08 Neurimmune Ag Novel potency assay for antibody-based drugs and useful means therefor
WO2024105092A1 (en) 2022-11-15 2024-05-23 Neurimmune Ag Pharmaceutical compositions for treating or preventing transthyretin-mediated amyloidosis

Also Published As

Publication number Publication date
TW202528347A (zh) 2025-07-16
WO2025104243A1 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
McLure et al. A comparative HST imaging study of the host galaxies of radio-quiet quasars, radio-loud quasars and radio galaxies—I
CY1121162T1 (el) M-csf-ειδικο μονοκλωνικο αντισωμα και χρησεις αυτου
CL2021000293A1 (es) Anticuerpos anti-trem2 y métodos relacionados (divisional de solicitud no.202001575)
CL2021001541A1 (es) Un complejo novedoso que comprende un péptido penetrante de células, una carga y un agonista de péptido de tlr para tratamiento de cáncer colorrectal (divisional de la solicitud no. 201900694)
CO2024013569A2 (es) Moléculas de unión contra frα
CO2023011463A2 (es) Nuevos anticuerpos anti-cd24
CL2010000791A1 (es) Anticuerpo monoclonales que se unen a integrina alfavbeta6 (7.7g5), composicion; hibridoma que lo produce (atcc pta-3899); usos para preparar un medicamento para tratar fibrosis, psoriasis, cancer y otros. (divisional solicitud n° 513-03)
MX2024005727A (es) Formulaciones estables que comprenden un anticuerpo biespecifico para bcma/cd3.
MX2021013657A (es) Conjugados de anticuerpo y farmaco.
CL2022003723A1 (es) Anticuerpos de alta afinidad dirigidos a tau fosforilada en serina 413.
ECSP21044421A (es) Anticuerpos anti-pmel17 y conjugados de los mismos
Hasanpourghadi et al. Targeting of tubulin polymerization and induction of mitotic blockage by Methyl 2-(5-fluoro-2-hydroxyphenyl)-1 H-benzo [d] imidazole-5-carboxylate (MBIC) in human cervical cancer HeLa cell
ECSP23042551A (es) Conjugados de anticuerpo y fármaco
AR128060A1 (es) Complejos polipeptídicos de unión a antígeno activados condicionalmente y métodos de uso de los mismos
CO2023016712A2 (es) Conjugados de neodegradador-anticuerpo anti-cd33
CL2025001171A1 (es) Compuestos que median la degradacion de proteinas y metodos de uso de los mismos
Mitta et al. A new morphotype of lower jaw associated with Calliphylloceras (Cephalopoda: Ammonoidea) from the Middle Jurassic of the Northern Caucasus
AR134366A1 (es) Anticuerpo antitranstiretina, composiciones que comprenden dicho anticuerpo y métodos para tratar o prevenir la amiloidosis mediada por transtiretina
Lake et al. Translations of the practice environment scale of the nursing work index: a systematic review
Mora‐Navarro et al. Synthetic antimicrobial β‐peptide in dual‐treatment with fluconazole or ketoconazole enhances the in vitro inhibition of planktonic and biofilm Candida albicans
CL2023002992A1 (es) Anticuerpos anti-c-met y conjugados de anticuerpo-fármaco
Lin et al. Cytotoxic and biomechanical effects of clinical dosing schemes of paclitaxel on neurons and cancer cells
Kaufman et al. Optical clearing of small intestine for three‐dimensional visualization of cellular proliferation within crypts
MX2024012400A (es) Metodos para activacion y expansion de celulas asesinas naturales modificadas y combinaciones con anticuerpos
McLure et al. A comparative hst imaging study of the host galaxies of radio-quiet quasars, radio-loud quasars and radio galaxies: paper I